利德曼(300289) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥167,677,605.14, a decrease of 0.66% compared to the same period last year, while year-to-date revenue increased by 30.81% to ¥541,955,931.31[4] - Net profit attributable to shareholders for Q3 2022 was ¥10,533,956.80, down 32.01% year-on-year, with year-to-date net profit increasing by 18.62% to ¥34,469,678.83[4] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥8,682,676.22, a decrease of 43.57% year-on-year, while year-to-date it increased by 10.97% to ¥29,757,670.58[4] - Total operating revenue for the third quarter reached ¥541,955,931.31, an increase of 30.8% compared to ¥414,305,890.57 in the same period last year[23] - Net profit for the period was ¥49,863,077.17, slightly down from ¥50,012,250.46 in the previous year, representing a decrease of 0.3%[24] - The net profit attributable to shareholders of the parent company was ¥34,469,678.83, an increase of 18.3% compared to ¥29,057,757.37 in the same period last year[24] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥78,295,528.10, an increase of 58.81% compared to the previous year[4] - The cash inflow from operating activities for Q3 2022 was CNY 667,753,861.95, an increase of 26.9% compared to CNY 525,904,241.09 in Q3 2021[27] - The cash flow from operating activities netted CNY 78,295,528.10, which is a 58.8% increase compared to CNY 49,300,438.01 in Q3 2021[27] - The cash received from other operating activities was CNY 11,647,624.61, compared to CNY 9,669,930.04, marking a 20.5% increase[27] Operating Costs - Operating costs increased by 56.40% year-to-date, mainly due to the purchase of COVID-19 testing reagents[9] - Total operating costs amounted to ¥478,638,335.45, up 36.3% from ¥350,959,659.12 year-on-year[23] - The cash paid for purchasing goods and services was CNY 374,893,475.53, up from CNY 274,669,214.59, indicating a 36.4% increase in operational costs[27] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,338,864,516.45, a decrease of 0.41% from the end of the previous year[4] - Total liabilities amounted to ¥322,499,967.10, a decrease from ¥370,301,842.38 at the end of the previous period[23] - The company has a total asset value of 2,338,864,516.45 CNY as of September 30, 2022, down from 2,348,410,268.66 CNY at the beginning of the year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,378[13] - The largest shareholder, Guangzhou High-tech Zone Technology Holding Group Co., Ltd., holds 46.35% of shares, totaling 252,133,152 shares[13] Research and Development - Research and development expenses for the quarter were ¥28,351,916.96, up from ¥24,493,747.55 year-on-year, indicating a focus on innovation[23] - The company has added 8 new patent authorizations during the reporting period, including a method for detecting invasive fungal infections[17] Investment Activities - The net cash outflow from investing activities was CNY -327,437,026.83, compared to CNY -25,002,514.27 in the same period last year, indicating a significant increase in investment expenditures[27] - The company reported a significant increase in cash outflows for investment activities, totaling CNY 660,432,992.86, compared to CNY 59,171,716.40 in the previous year[27] Goodwill and Other Assets - The company has a total of 190,072,267.77 CNY in goodwill, unchanged from the beginning of the year[20] - The company has a total of 149,905,196.83 CNY in investment properties as of September 30, 2022[20]